Home  |  Contact

Cellosaurus U2OS (CVCL_0042)

Cell line name U2OS
Synonyms U-2 OS; U-2OS; U-2-OS; U2-OS; U20-S; U20S; 2T
Accession CVCL_0042
Secondary accession CVCL_L856
Resource Identification Initiative To cite this cell line use: U2OS (RRID:CVCL_0042)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: ENCODE project common cell types; tier 3.
Part of: MD Anderson Cell Lines Project.
Doubling time: ~25-30 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Cell surface proteome.
Omics: Deep antibody staining analysis.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Metabolome analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Omics: Virome analysis using proteomics.
Misspelling: U-205; Occasionally.
Misspelling: U205; Occasionally.
HLA typing Source: PubMed=25960936
Class I
HLA-AA*32:01,02:01
HLA-BB*44:02,44:02
HLA-CC*05:01,07:04
Class II
HLA-DQDQB1*05:03,03:04
HLA-DRDRB1*04:05,04:05
Disease Osteosarcoma (NCIt: C9145)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_KV94 (cAMP Hunter U2OS HTR7B Gs)CVCL_KV95 (cAMP Hunter U2OS mGLP1R Gs)CVCL_KW11 (InCELL Hunter U2OS BCL2-BAX Protein Binding)
CVCL_KW12 (InCELL Hunter U2OS BCL2-BIM Protein Binding)CVCL_KW13 (InCELL Hunter U2OS BCL2L1-BAX Protein Binding)CVCL_KW14 (InCELL Hunter U2OS BCL2L1-BIM Protein Binding)
CVCL_KW15 (InCELL Hunter U2OS MCL1-BIM Protein Binding)CVCL_KZ71 (PathHunter U2OS ADCYAP1R1 Total GPCR Internalization)CVCL_KZ72 (PathHunter U2OS ADRA2C Total GPCR Internalization)
CVCL_KZ73 (PathHunter U2OS AGTRL1 Activated GPCR Internalization)CVCL_KZ74 (PathHunter U2OS AHR Protein Interaction)CVCL_KZ75 (PathHunter U2OS AVPR1A beta-arrestin)
CVCL_KZ76 (PathHunter U2OS AVPR1A Total GPCR Internalization)CVCL_KZ77 (PathHunter U2OS AVPR1B Activated GPCR Internalization)CVCL_KZ78 (PathHunter U2OS AVPR2 Activated GPCR Internalization)
CVCL_KZ79 (PathHunter U2OS BDKRB2 Activated GPCR Internalization)CVCL_KZ80 (PathHunter U2OS beta-arrestin1-EA Parental)CVCL_KZ81 (PathHunter U2OS beta-arrestin2-EA Parental)
CVCL_KZ82 (PathHunter U2OS beta-Catenin Nuclear Translocation)CVCL_KZ83 (PathHunter U2OS C3AR1 Activated GPCR Internalization)CVCL_KZ84 (PathHunter U2OS C3AR1 beta-arrestin)
CVCL_KZ85 (PathHunter U2OS C5AR1 Activated GPCR Internalization)CVCL_KZ86 (PathHunter U2OS C5L2 Activated GPCR Internalization)CVCL_KZ87 (PathHunter U2OS CALCR beta-arrestin)
CVCL_KZ88 (PathHunter U2OS CCKAR Activated GPCR Internalization)CVCL_KZ89 (PathHunter U2OS CCKBR Activated GPCR Internalization)CVCL_KZ90 (PathHunter U2OS CCR1 Activated GPCR Internalization)
CVCL_KZ91 (PathHunter U2OS CCR1 beta-arrestin-1)CVCL_KZ92 (PathHunter U2OS CCR10 Activated GPCR Internalization)CVCL_KZ93 (PathHunter U2OS CCR10 beta-arrestin)
CVCL_KZ94 (PathHunter U2OS CCR2 Total GPCR Internalization)CVCL_KZ95 (PathHunter U2OS CCR4 Total GPCR Internalization)CVCL_KZ96 (PathHunter U2OS CCR5 Activated GPCR Internalization)
CVCL_KZ97 (PathHunter U2OS CCR6 Activated GPCR Internalization)CVCL_KZ98 (PathHunter U2OS CCR7 Activated GPCR Internalization)CVCL_KZ99 (PathHunter U2OS CDC25A Degradation)
CVCL_LA00 (PathHunter U2OS CHRM1 Activated GPCR Internalization)CVCL_LA01 (PathHunter U2OS CHRM1 beta-arrestin)CVCL_LA02 (PathHunter U2OS CHRM2 Activated GPCR Internalization)
CVCL_LA03 (PathHunter U2OS CHRM3 beta-arrestin)CVCL_LA04 (PathHunter U2OS CHRM3 Total GPCR Internalization)CVCL_LA05 (PathHunter U2OS CHRM4 Total GPCR Internalization)
CVCL_LA06 (PathHunter U2OS CHRM5 Activated GPCR Internalization)CVCL_LA07 (PathHunter U2OS CMKLR1 Activated GPCR Internalization)CVCL_LA08 (PathHunter U2OS CRHR1 Activated GPCR Internalization)
CVCL_LA09 (PathHunter U2OS CRHR2 Activated GPCR Internalization)CVCL_LA10 (PathHunter U2OS CRTH2 beta-arrestin)CVCL_LA11 (PathHunter U2OS CXCR1 Activated GPCR Internalization)
CVCL_LA12 (PathHunter U2OS CXCR1 beta-arrestin)CVCL_LA13 (PathHunter U2OS CXCR2 Activated GPCR Internalization)CVCL_LA14 (PathHunter U2OS CXCR3 Activated GPCR Internalization)
CVCL_LA15 (PathHunter U2OS CXCR3 beta-arrestin)CVCL_LA16 (PathHunter U2OS CXCR4 Total GPCR Internalization)CVCL_RQ22 (PathHunter U2OS CXCR5 beta-arrestin)
CVCL_LA17 (PathHunter U2OS CXCR6 Total GPCR Internalization)CVCL_LA18 (PathHunter U2OS CXCR7 Activated GPCR Internalization)CVCL_LA19 (PathHunter U2OS DRD1 Total GPCR Internalization)
CVCL_LA20 (PathHunter U2OS DRD3 beta-arrestin)CVCL_LA21 (PathHunter U2OS EBI2 Total GPCR Internalization)CVCL_LA22 (PathHunter U2OS EDG2 Activated GPCR Internalization)
CVCL_LA23 (PathHunter U2OS EDG3 Activated GPCR Internalization)CVCL_LA24 (PathHunter U2OS EDG5 Activated GPCR Internalization)CVCL_LA25 (PathHunter U2OS EDG7 Activated GPCR Internalization)
CVCL_LA26 (PathHunter U2OS EDNRB Total GPCR Internalization)CVCL_LA27 (PathHunter U2OS F2RL1 Activated GPCR Internalization)CVCL_LA28 (PathHunter U2OS F2RL1 beta-arrestin)
CVCL_LA29 (PathHunter U2OS F2RL3 Activated GPCR Internalization)CVCL_LA30 (PathHunter U2OS FOXO3 Nuclear Translocation)CVCL_LA31 (PathHunter U2OS FPR1 Total GPCR Internalization)
CVCL_LA32 (PathHunter U2OS FPRL1 Activated GPCR Internalization)CVCL_LA33 (PathHunter U2OS GALR1 Total GPCR Internalization)CVCL_LA34 (PathHunter U2OS GHSR1a beta-arrestin-1)
CVCL_LA35 (PathHunter U2OS GLP1R Activated GPCR Internalization)CVCL_LA36 (PathHunter U2OS GLP1R Total GPCR Internalization)CVCL_LA37 (PathHunter U2OS GLP2R Activated GPCR Internalization)
CVCL_LA38 (PathHunter U2OS GPBAR1 beta-arrestin)CVCL_LA39 (PathHunter U2OS GPR1 Total GPCR Internalization)CVCL_LA40 (PathHunter U2OS GPR119 beta-arrestin)
CVCL_LA41 (PathHunter U2OS GPR17 beta-arrestin)CVCL_LA42 (PathHunter U2OS GPR22 beta-arrestin)CVCL_LA43 (PathHunter U2OS GPR35 Activated GPCR Internalization)
CVCL_LA44 (PathHunter U2OS GPR52 beta-arrestin)CVCL_LA45 (PathHunter U2OS GPR6 beta-arrestin)CVCL_LA46 (PathHunter U2OS GPR85 beta-arrestin)
CVCL_LA47 (PathHunter U2OS GRPR Activated GPCR Internalization)CVCL_LA48 (PathHunter U2OS GRPR beta-arrestin)CVCL_LA49 (PathHunter U2OS HCRTR1 Total GPCR Internalization)
CVCL_LA50 (PathHunter U2OS HCRTR2 Total GPCR Internalization)CVCL_LA51 (PathHunter U2OS HRH4 beta-arrestin)CVCL_LA52 (PathHunter U2OS HTR1B beta-arrestin)
CVCL_LA53 (PathHunter U2OS HTR1E beta-arrestin)CVCL_LA54 (PathHunter U2OS HTR1F beta-arrestin)CVCL_LA55 (PathHunter U2OS HTR2A beta-arrestin)
CVCL_LA56 (PathHunter U2OS HTR2A Total GPCR Internalization)CVCL_LA57 (PathHunter U2OS HTR2C Activated GPCR Internalization)CVCL_LA58 (PathHunter U2OS HTR2C beta-arrestin)
CVCL_LA59 (PathHunter U2OS HTR2C(VGV) beta-arrestin)CVCL_LA60 (PathHunter U2OS HTR2C(VNV) beta-arrestin)CVCL_LA61 (PathHunter U2OS HTR2C(VSV) beta-arrestin)
CVCL_LA62 (PathHunter U2OS HTR5A beta-arrestin)CVCL_LA63 (PathHunter U2OS IkappaB Degradation)CVCL_LA64 (PathHunter U2OS Keap1-NRF2 Nuclear Translocation)
CVCL_LA65 (PathHunter U2OS KISS1R beta-arrestin)CVCL_LA66 (PathHunter U2OS LTB4R Total GPCR Internalization)CVCL_LA67 (PathHunter U2OS MC1R beta-arrestin)
CVCL_LA68 (PathHunter U2OS MC3R beta-arrestin)CVCL_LA69 (PathHunter U2OS MC3R Total GPCR Internalization)CVCL_LA70 (PathHunter U2OS MC4R beta-arrestin)
CVCL_LA71 (PathHunter U2OS MC5R beta-arrestin)CVCL_LA72 (PathHunter U2OS mCCR1 beta-arrestin)CVCL_LA73 (PathHunter U2OS mCCR2 beta-arrestin)
CVCL_LA74 (PathHunter U2OS MCHR1 beta-arrestin)CVCL_LA75 (PathHunter U2OS MCHR1 beta-arrestin-1)CVCL_LA76 (PathHunter U2OS MCHR1 Total GPCR Internalization)
CVCL_LA77 (PathHunter U2OS MCHR2 beta-arrestin)CVCL_LA78 (PathHunter U2OS mCXCR4 beta-arrestin)CVCL_LA79 (PathHunter U2OS mCXCR7 beta-arrestin)
CVCL_LA80 (PathHunter U2OS mFFAR1 beta-arrestin)CVCL_LA81 (PathHunter U2OS mGIPR beta-arrestin)CVCL_LA82 (PathHunter U2OS mHTR2C beta-arrestin)
CVCL_LA83 (PathHunter U2OS MLNR Activated GPCR Internalization)CVCL_LA84 (PathHunter U2OS mNPY1R beta-arrestin)CVCL_LA85 (PathHunter U2OS mOPRM1 beta-arrestin)
CVCL_LA86 (PathHunter U2OS mP2RY12 beta-arrestin)CVCL_LA87 (PathHunter U2OS MTNR1B Total GPCR Internalization)CVCL_LA88 (PathHunter U2OS NMBR Total GPCR Internalization)
CVCL_LA89 (PathHunter U2OS NMU1R beta-arrestin)CVCL_LA90 (PathHunter U2OS NMU1R Total GPCR Internalization)CVCL_LA91 (PathHunter U2OS NPSR1 beta-arrestin)
CVCL_LA92 (PathHunter U2OS NPY2R Activated GPCR Internalization)CVCL_LA93 (PathHunter U2OS NTSR1 Activated GPCR Internalization)CVCL_LA94 (PathHunter U2OS OPRD1 Activated GPCR Internalization)
CVCL_LA95 (PathHunter U2OS OPRD1 beta-arrestin)CVCL_LA96 (PathHunter U2OS OPRD1 beta-arrestin-1)CVCL_LA97 (PathHunter U2OS OPRK1 beta-arrestin)
CVCL_LA98 (PathHunter U2OS OPRK1 Total GPCR Internalization)CVCL_LA99 (PathHunter U2OS OPRL1 Total GPCR Internalization)CVCL_LB00 (PathHunter U2OS OPRM1 beta-arrestin)
CVCL_LB01 (PathHunter U2OS OPRM1 beta-arrestin-1)CVCL_LB02 (PathHunter U2OS OPRM1 Total GPCR Internalization)CVCL_LB03 (PathHunter U2OS OXER1 Total GPCR Internalization)
CVCL_LB04 (PathHunter U2OS OXTR Activated GPCR Internalization)CVCL_LB05 (PathHunter U2OS P2RY1 Activated GPCR Internalization)CVCL_LB06 (PathHunter U2OS P2RY1 beta-arrestin)
CVCL_LB07 (PathHunter U2OS P2RY12 Total GPCR Internalization)CVCL_LB08 (PathHunter U2OS P2RY2 Activated GPCR Internalization)CVCL_LB09 (PathHunter U2OS P2RY2 beta-arrestin)
CVCL_LB10 (PathHunter U2OS P2RY4 Activated GPCR Internalization)CVCL_LB11 (PathHunter U2OS p53 Nuclear Translocation)CVCL_LB12 (PathHunter U2OS PRalpha Protein Interaction)
CVCL_LB13 (PathHunter U2OS PRbeta Protein Interaction)CVCL_LB14 (PathHunter U2OS PRLHR Activated GPCR Internalization)CVCL_LB15 (PathHunter U2OS PROKR1 Total GPCR Internalization)
CVCL_LB16 (PathHunter U2OS PROKR2 Total GPCR Internalization)CVCL_LB17 (PathHunter U2OS PTAFR Activated GPCR Internalization)CVCL_LB18 (PathHunter U2OS PTGER1 beta-arrestin)
CVCL_LB19 (PathHunter U2OS PTGER4 Activated GPCR Internalization)CVCL_LB20 (PathHunter U2OS PTGER4 beta-arrestin)CVCL_LB21 (PathHunter U2OS PTGFR beta-arrestin)
CVCL_LB22 (PathHunter U2OS PTGFR Total GPCR Internalization)CVCL_LB23 (PathHunter U2OS PTGIR Total GPCR Internalization)CVCL_LB24 (PathHunter U2OS PTHR1 Activated GPCR Internalization)
CVCL_LB25 (PathHunter U2OS PTHR2 Total GPCR Internalization)CVCL_LB26 (PathHunter U2OS RANK-IkappaB Functional Assay)CVCL_LB27 (PathHunter U2OS rFFAR1 beta-arrestin)
CVCL_LB28 (PathHunter U2OS rHTR2C beta-arrestin)CVCL_LB29 (PathHunter U2OS RXFP3 Total GPCR Internalization)CVCL_LB30 (PathHunter U2OS RXRalpha Protein Interaction)
CVCL_LB31 (PathHunter U2OS SCTR Activated GPCR Internalization)CVCL_LB32 (PathHunter U2OS SREBP2 Nuclear Translocation)CVCL_LB33 (PathHunter U2OS SSTR1 beta-arrestin)
CVCL_LB34 (PathHunter U2OS SSTR5 beta-arrestin)CVCL_LB35 (PathHunter U2OS TACR1 Activated GPCR Internalization)CVCL_LB36 (PathHunter U2OS TACR2 Activated GPCR Internalization)
CVCL_LB37 (PathHunter U2OS TACR3 Activated GPCR Internalization)CVCL_LB38 (PathHunter U2OS TBXA2R Activated GPCR Internalization)CVCL_LB39 (PathHunter U2OS TBXA2R beta-arrestin)
CVCL_LB40 (PathHunter U2OS TORC1 Nuclear Translocation)CVCL_LB41 (PathHunter U2OS TORC2 Nuclear Translocation)CVCL_LB42 (PathHunter U2OS TORC3 Nuclear Translocation)
CVCL_LB43 (PathHunter U2OS TRHR Total GPCR Internalization)CVCL_LB44 (PathHunter U2OS TSHR(L) beta-arrestin)CVCL_LB45 (PathHunter U2OS TSHR(L) beta-arrestin-1)
CVCL_LB46 (PathHunter U2OS UTR2 Total GPCR Internalization)CVCL_LB47 (PathHunter U2OS VIPR1 Activated GPCR Internalization)CVCL_LB48 (PathHunter U2OS VIPR2 Total GPCR Internalization)
CVCL_LB49 (PathHunter U2OS XBP1 Nuclear Translocation)CVCL_T429 (U-2 OS R1)CVCL_V335 (U2-OS Tet-On)
CVCL_V336 (U2-OS-Luc Tet-On)CVCL_KU66 (U2OS CASR Gq)CVCL_KA03 (U2OS FKHR-EGFP)
CVCL_KA04 (U2OS FKHRL1-EGFP)CVCL_RQ90 (U2OS GFP-ACTB)CVCL_RQ91 (U2OS GFP-HMGA1)
CVCL_RQ92 (U2OS GFP-LMNB1)CVCL_RQ88 (U2OS GFP-NUP98)CVCL_RQ93 (U2OS GFP-TUBA1B)
CVCL_KU67 (U2OS GPR39 Gq)CVCL_KU68 (U2OS GRM1 Gq)CVCL_KU69 (U2OS GRM5 Gq)
CVCL_RJ63 (U2OS His10-SUMO-2-K0-Q87R)CVCL_KU70 (U2OS OXGR1 Gq)CVCL_RQ95 (U2OS RFP-ACTB)
CVCL_RQ94 (U2OS RFP-TUBA1B)CVCL_RQ87 (U2OS-S1P1)
Sex of cell Female
Age at sampling 15Y
Category Cancer cell line
STR profile Source(s): ATCC; CLS; Cosmic-CLP; DSMZ; ECACC; KCLB; PubMed=25877200

Markers:
AmelogeninX
CSF1PO13 (ATCC; Cosmic-CLP; ECACC; KCLB; PubMed=25877200)
12,13 (CLS; DSMZ)
D13S31713 (ATCC; Cosmic-CLP; DSMZ; ECACC; KCLB; PubMed=25877200)
11,13 (CLS)
D16S53911,12
D18S5112,14 (CLS)
14 (PubMed=25877200)
D21S1131
D3S135816
D5S81811 (ATCC; Cosmic-CLP; ECACC; KCLB; PubMed=25877200)
8,11 (CLS; DSMZ)
D7S82011,12 (ATCC; CLS; Cosmic-CLP; DSMZ; ECACC; KCLB)
12 (PubMed=25877200)
D8S117912,14
FGA20
Penta D9
Penta E10,13
TH016,9.3
TPOX11,12
vWA14,18
Web pages http://141.61.102.20/mxdb/project/show/9191407937500
http://www.proteinatlas.org/learn/cellines
http://www.cells-talk.com/index.php/page/copelibrary?key=U2-OS
http://micro.magnet.fsu.edu/primer/techniques/fluorescence/gallery/cells/u2/u2cells.html
http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/u/cell-lines-detail-92.html
http://genome.ucsc.edu/ENCODE/protocols/cell/human/U2OS_Farnham_protocol.pdf
http://tcpaportal.org/mclp/
Publications

PubMed=6081590; DOI=10.1002/ijc.2910020505
Ponten J., Saksela E.
Two established in vitro cell lines from human mesenchymal tumours.
Int. J. Cancer 2:434-447(1967)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=7017212; DOI=10.1093/jnci/66.6.1003
Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.
HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.
J. Natl. Cancer Inst. 66:1003-1012(1981)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=2823272; DOI=10.1073/pnas.84.21.7716
Masuda H., Miller C., Koeffler H.P., Battifora H., Cline M.J.
Rearrangement of the p53 gene in human osteogenic sarcomas.
Proc. Natl. Acad. Sci. U.S.A. 84:7716-7719(1987)

PubMed=8275086; DOI=10.1038/ng1193-230
Galili N., Davis R.J., Fredericks W.J., Mukhopadhyay S., Rauscher F.J. III, Emanuel B.S., Rovera G., Barr F.G.
Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma.
Nat. Genet. 5:230-235(1993)

PubMed=8617485; DOI=10.1016/S0046-8177(96)90115-X
Scotlandi K., Serra M., Manara M.C., Benini S., Sarti M., Maurici D., Lollini P.-L., Picci P., Bertoni F., Baldini N.
Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor.
Hum. Pathol. 27:408-416(1996)

PubMed=12645653; DOI=10.1016/S0165-4608(02)00685-4
Ozaki T., Neumann T., Wai D.H., Schaefer K.-L., van Valen F., Lindner N., Scheel C., Bocker W., Winkelmann W., Dockhorn-Dworniczak B., Horst J., Poremba C.
Chromosomal alterations in osteosarcoma cell lines revealed by comparative genomic hybridization and multicolor karyotyping.
Cancer Genet. Cytogenet. 140:145-152(2003)

PubMed=15150091; DOI=10.1158/0008-5472.CAN-03-0809
Schaefer K.-L., Brachwitz K., Wai D.H., Braun Y., Diallo R., Korsching E., Eisenacher M., Voss R., van Valen F., Baer C., Selle B., Spahn L., Liao S.-K., Lee K.A.W., Hogendoorn P.C.W., Reifenberger G., Gabbert H.E., Poremba C.
Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3.
Cancer Res. 64:3395-3405(2004)

PubMed=15736406
Pautke C., Schieker M., Tischer T., Kolk A., Neth P., Mutschler W., Milz S.
Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts.
Anticancer Res. 24:3743-3748(2004)

PubMed=18359981
Niforou K.M., Anagnostopoulos A.K., Vougas K., Kittas C., Gorgoulis V.G., Tsangaris G.T.
The proteome profile of the human osteosarcoma U2OS cell line.
Cancer Genomics Proteomics 5:63-78(2008)

PubMed=19787792; DOI=10.1002/gcc.20717
Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S., Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H., Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W., Buerger H., Aigner T., Gabbert H.E., Poremba C.
Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort.
Genes Chromosomes Cancer 49:40-51(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=21519327; DOI=10.1038/labinvest.2011.72
Mohseny A.B., Machado I., Cai Y., Schaefer K.-L., Serra M., Hogendoorn P.C.W., Llombart-Bosch A., Cleton-Jansen A.-M.
Functional characterization of osteosarcoma cell lines provides representative models to study the human disease.
Lab. Invest. 91:1195-1205(2011)

PubMed=22068332; DOI=10.1038/msb.2011.82
Beck M., Schmidt A., Malmstroem J., Claassen M., Ori A., Szymborska A., Herzog F., Rinner O., Ellenberg J., Aebersold R.
The quantitative proteome of a human cell line.
Mol. Syst. Biol. 7:549-549(2011)

PubMed=22278370; DOI=10.1074/mcp.M111.014050
Geiger T., Wehner A., Schaab C., Cox J., Mann M.
Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins.
Mol. Cell. Proteomics 11:M111.014050-M111.014050(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=24618588; DOI=10.1371/journal.pone.0091433
Chernobrovkin A.L., Zubarev R.A.
Detection of viral proteins in human cells lines by xeno-proteomics: elimination of the last valid excuse for not testing every cellular proteome dataset for viral proteins.
PLoS ONE 9:E91433-E91433(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:E954893-E954893(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25894527; DOI=10.1371/journal.pone.0121314
Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F., Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R., Schmidt A., Mirkowska P., Hartlova A., Van Eyk J.E., Bourquin J.-P., Aebersold R., Boheler K.R., Zandstra P., Wollscheid B.
A mass spectrometric-derived cell surface protein atlas.
PLoS ONE 10:E0121314-E0121314(2015)

PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074
Teicher B.A., Polley E., Kunkel M., Evans D., Silvers T.E., Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J., Harris E., Monks A., Morris J.
Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.
Mol. Cancer Ther. 14:2452-2462(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections ATCC; HTB-96
BCRC; 60187
BCRJ; 0304
CLS; 300364/p489_U-2_OS
DSMZ; ACC-785
ECACC; 92022711
ICLC; HTL11001
KCB; KCB 200962YJ
KCLB; 30096
Cell line databases/resources CLDB; cl53
CLDB; cl4579
CLDB; cl4580
CLDB; cl4581
CLDB; cl7217
CCLE; U2OS_BONE
CCRID; 3111C0001CCC000028
CCRID; 3131C0001000700088
Cosmic-CLP; 909776
GDSC; 909776
LINCS_LDP; LCL-1431
Lonza; 676
TOKU-E; 3379
Ontologies BTO; BTO:0001938
CLO; CLO_0001272
CLO; CLO_0009454
EFO; EFO_0002869
MCCL; MCC:0000468
Biological sample resources 4DN; 4DNSR3V9ST6H
BioSample; SAMN03472549
BioSample; SAMN03472766
ENCODE; ENCBS200HLU
ENCODE; ENCBS266AAA
ENCODE; ENCBS953RZO
Chemistry resources ChEMBL-Cells; CHEMBL3307757
ChEMBL-Targets; CHEMBL615023
Gene expression databases ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSE54820
GEO; GSM170250
GEO; GSM185160
GEO; GSM185161
GEO; GSM287989
GEO; GSM287990
GEO; GSM320831
GEO; GSM827583
GEO; GSM879223
GEO; GSM887722
GEO; GSM888816
GEO; GSM1231597
GEO; GSM1231598
GEO; GSM1231599
GEO; GSM1231600
GEO; GSM1231601
GEO; GSM1231602
GEO; GSM1231603
GEO; GSM1231604
GEO; GSM1231605
GEO; GSM1231606
GEO; GSM1231607
GEO; GSM1231608
GEO; GSM1231609
GEO; GSM1231610
GEO; GSM1356565
GEO; GSM1356566
GEO; GSM1356567
GEO; GSM1356568
GEO; GSM1356569
GEO; GSM1356570
GEO; GSM1356571
GEO; GSM1356572
GEO; GSM1356573
GEO; GSM1356574
GEO; GSM1356575
GEO; GSM1356576
GEO; GSM1356577
GEO; GSM1356578
GEO; GSM1356579
GEO; GSM1356580
GEO; GSM1356581
GEO; GSM1356582
GEO; GSM1356583
GEO; GSM1356584
GEO; GSM1356585
GEO; GSM1356586
GEO; GSM1356587
GEO; GSM1670557
GEO; GSM1676324
GEO; GSM1701657
Metabolomic databases MetaboLights; MTBLS292
Other Wikidata; Q28473037
Polymorphism and mutation databases Cosmic; 687934
Cosmic; 755312
Cosmic; 909776
Cosmic; 931038
Cosmic; 931909
Cosmic; 1044081
Cosmic; 1044268
Cosmic; 1066238
Cosmic; 1074397
Cosmic; 1078392
Cosmic; 1082493
Cosmic; 1097758
Cosmic; 1529905
Cosmic; 1733128
Cosmic; 2009542
Cosmic; 2301583
Cosmic; 2440477
Proteomic databases PRIDE; PRD000118
PRIDE; PXD000262
PRIDE; PXD000157
PRIDE; PXD000589
PRIDE; PXD000953
PRIDE; PXD000954
PRIDE; PXD001220
PRIDE; PXD002073
PRIDE; PXD002117
PRIDE; PXD002395
PRIDE; PXD003754